| Literature DB >> 23015843 |
Hiroki Oguri1, Haruki Mizoguchi, Hideaki Oikawa, Aki Ishiyama, Masato Iwatsuki, Kazuhiko Otoguro, Satoshi Omura.
Abstract
By emulating the universal biosynthetic strategy, which employs modular assembly and divergent cyclizations, we have developed a four-step synthetic process to yield a collection of natural-product-inspired scaffolds. Modular assembly of building blocks onto a piperidine-based manifold 6, having a carboxylic acid group, was achieved through Ugi condensation, N-acetoacetylation and diazotransfer, leading to cyclization precursors. The rhodium-catalyzed tandem cyclization and divergent cycloaddition gave rise to tetracyclic and hexacyclic scaffolds by the appropriate choice of dipolarophiles installed at modules 3 and 4. A different piperidine-based manifold 15 bearing an amino group was successfully applied to demonstrate the flexibility and scope of the unified four-step process for the generation of structural diversity in the fused scaffolds. Evaluation of in vitro antitrypanosomal activities of the collections and preliminary structure-activity relationship (SAR) studies were also undertaken.Entities:
Keywords: chemical diversity; divergent cyclization; indole alkaloids; modular assembly; rhodium-catalyzed cyclization–cycloaddition; skeletal and stereochemical diversity
Year: 2012 PMID: 23015843 PMCID: PMC3388883 DOI: 10.3762/bjoc.8.105
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Figure 1(a) Biosynthetic outline of aromatic polyketides; (b) structure of indole alkaloids composed of indole (red) and piperidine (blue) groups; (c) divergent cyclizations to generate scaffold variations as an illustration of the “Build-Couple-Pair” strategy in diversity-oriented synthesis.
Figure 2(a) Synthetic plans based on modular assembly and divergent cyclizations leading to fused skeletons; (b) structures of naturally occurring alkaloids bearing aminoacetal moieties and a proposed mode of action of quinocarcin.
Scheme 1Four-step synthesis of hexacyclic skeleton 25.
Scheme 2Four-step synthesis of hexacyclic skeleton 30.
Scheme 3Parallel and four-step synthesis of tetracyclic skeletons 39–42 and 47–48.
Scheme 4Synthesis of branched precursors, 51 and 52, using amines 49 and 50, with different methylene lengths and attempts to switch reaction sites.
Scheme 5Four-step synthesis of hexacyclic scaffold 63 employing manifold 15. For details of the synthesis of 60 and 61 see Supporting Information File 1.
In vitro anti-trypanosomal activities of natural product analogues and approved drugs against T. brucei brucei GUTat 3.1a.
| entry | compound | IC50 (μg/mL) | Selectivity | |
| anti-trypanosomal | cytotoxicity | |||
| 1 | >12.5 | NDb | (─) | |
| 2 | 0.46 | 4.02 | 8.7 | |
| 3 | 5.89 | 34.64 | 5.9 | |
| 4 | >12.5 | NDb | (─) | |
| 5 | 5.9 | 24.47 | 4.1 | |
| 6 | >12.5 | NDb | (─) | |
| 7 | >12.5 | NDb | (─) | |
| 8 | pentamidinec | 0.00158 | 5.71 | 3600 |
| 9 | suraminc | 1.58 | >100 | >63 |
| 10 | eflornithinec | 2.27 | >100 | >44 |
aCulture of trypanosome (2.0–2.5 × 104 trypanosomes/mL for GUTat 3.1 strain) was used. The cytotoxicities were evaluated with MRC-5 cells, and the selectivity index (SI) for trypanosomiasis was calculated as (IC50 for MRC-5)/(IC50 for T. brucei brucei). bND means “not determined”. cExisting antitrypanosomal drugs.